On 22 September, the United States' top public-health officials stood alongside President Donald Trump at the White House and delivered a message that went around the world in an instant. The US Food and Drug Administration (FDA) said it intends to change its guidance on acetaminophen - also known as paracetamol - a household painkiller marketed in the United States as Tylenol.
The guidance comes under the commission's new chairman, Paul Atkins, a Trump appointee who is a contrast with previous leadership that sought to block the approval of Bitcoin ETFs.